# OPTIMISE-CKD Drug Utilization

> **NCT05932901** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2682052 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05932901
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-04
- **Primary completion:** 2023-09-28
- **Final completion:** 2023-09-28
- **Target enrollment:** 2682052 (ACTUAL)
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05932901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05932901, "OPTIMISE-CKD Drug Utilization". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05932901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*